{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:33:41Z","timestamp":1793183621870,"version":"4.5.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"UKRI","doi-asserted-by":"publisher","award":["MR\/S034919\/1"],"award-info":[{"award-number":["MR\/S034919\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Welcome Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Research Career Development Fellowship"},{"name":"Australian Commonwealth Government"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Over the last decade, treatment options for moderate-to-severe ulcerative colitis (UC) have expanded. However, comparative studies between these agents are limited, especially among biologic-naive patients. We aimed to compare the persistence, effectiveness, and safety of tofacitinib and vedolizumab as the first advanced treatment for patients with UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who received either tofacitinib or vedolizumab as their first advanced therapy for UC in NHS Lothian were included. We used inverse probability of treatment weighting. The probability of treatment assignment was calculated via logistic regression using age, sex, UC duration, Montreal extent, C-reactive protein, concomitant corticosteroids, and partial Mayo score at drug commencement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included n\u2005=\u2005158 patients, of whom n\u2005=\u200581 (51.3%) received vedolizumab and n\u2005=\u200577 (48.7%) tofacitinib. Median follow-up for vedolizumab patients was 3.1 years (interquartile range [IQR] 1.6-4.8) and for tofacitinib patients 1.5 years (IQR 0.3-2.3). The cohort was 59.5% male with a median age of 41.1 years (IQR 31.5-51.8). At 2 years, vedolizumab persistence was superior to tofacitinib (p\u2005=\u20050.005). At Weeks 12 and 52, clinical, biochemical, and fecal biomarker steroid-free remission were comparable between groups. Primary nonresponse and secondary loss of response were 9.9% and 17.3% for vedolizumab and 23.4% and 13% for tofacitinib, respectively. The frequency of adverse events was comparable (11 [13.6%] vedolizumab vs 19 [24.7%] tofacitinib, p\u2005=\u20050.629).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found that the persistence and tolerability of vedolizumab were superior to tofacitinib in bio-naive UC, although the rates of clinical and biomarker remission were comparable. These data may help inform the positioning of advanced therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae188","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T15:30:03Z","timestamp":1733758203000},"source":"Crossref","is-referenced-by-count":5,"title":["Tofacitinib Versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5628-313X","authenticated-orcid":false,"given":"Beatriz","family":"Gros","sequence":"first","affiliation":[{"name":"Edinburgh IBD Unit, Western General Hospital , Edinburgh ,","place":["UK"]},{"name":"Department of Gastroenterology and Hepatology, Reina Sof\u00eda University Hospital, IMIBIC, University of C\u00f3rdoba , C\u00f3rdoba ,","place":["Spain"]},{"name":"Biomedical Research Center in Hepatic and Digestive Disease, CIBEREHD , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4437-8713","authenticated-orcid":false,"given":"Nathan","family":"Constantine-Cooke","sequence":"additional","affiliation":[{"name":"Centre for Genomics and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital , Edinburgh ,","place":["UK"]},{"name":"MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital , Edinburgh ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3860-3977","authenticated-orcid":false,"given":"Jake","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, Western General Hospital , Edinburgh ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6144-1369","authenticated-orcid":false,"given":"Alexander T","family":"Elford","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, Western General Hospital , Edinburgh ,","place":["UK"]},{"name":"Faculty of Medicine, The University of Melbourne , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"O\u2019Hare","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, Western General Hospital , Edinburgh ,","place":["UK"]},{"name":"Edinburgh Pharmacy Unit, Western General Hospital , Edinburgh ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Noble","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, Western General Hospital , Edinburgh ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth-Rhys","family":"Jones","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, Western General Hospital , Edinburgh ,","place":["UK"]},{"name":"Centre for Inflammation Research, The Queen\u2019s Medical Research Institute, University of Edinburgh , Edinburgh ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D","family":"Arnott","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, Western General Hospital , Edinburgh ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie W","family":"Lees","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, Western General Hospital , Edinburgh ,","place":["UK"]},{"name":"MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital , Edinburgh ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-8759","authenticated-orcid":false,"given":"Nikolas","family":"Plevris","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, Western General Hospital , Edinburgh ,","place":["UK"]},{"name":"MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital , Edinburgh ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"2025071505214413400_CIT0001","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"2025071505214413400_CIT0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025071505214413400_CIT0003","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jclinepi.2009.07.013","article-title":"Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials","volume":"63","author":"Freemantle","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2025071505214413400_CIT0004","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025071505214413400_CIT0005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ueg2.12492","article-title":"Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: a multicenter international study","volume":"12","author":"Allocca","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"2025071505214413400_CIT0006","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ibd\/izad087","article-title":"1-Year comparative effectiveness of tofacitinib vs ustekinumab for patients with ulcerative colitis and prior antitumor necrosis factor failure","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025071505214413400_CIT0007","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13\u00a0222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025071505214413400_CIT0008","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2025071505214413400_CIT0009","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2025071505214413400_CIT0010","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1136\/gutjnl-2019-318936","article-title":"IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology","volume":"68","author":"Jones","year":"2019","journal-title":"Gut"},{"key":"2025071505214413400_CIT0011","volume-title":"Janus Kinase Inhibitors (JAKi)\u2014Referral","author":"European Medicines Agency","year":"2023"},{"key":"2025071505214413400_CIT0012","first-page":"1","article-title":"mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"2025071505214413400_CIT0013","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2307\/2531492","article-title":"Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data","volume":"45","author":"Pepe","year":"1989","journal-title":"Biometrics"},{"key":"2025071505214413400_CIT0014","volume-title":"Health Research Authority Guidance"},{"key":"2025071505214413400_CIT0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cgh.2018.05.026","article-title":"Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases","volume":"17","author":"Feagan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025071505214413400_CIT0016","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2021.02.043","article-title":"Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025071505214413400_CIT0017","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/ecco-jcc\/jjz042","article-title":"Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the Scottish Vedolizumab Cohort","volume":"13","author":"Plevris","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025071505214413400_CIT0018","doi-asserted-by":"crossref","first-page":"17562848241258372","DOI":"10.1177\/17562848241258372","article-title":"Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis","volume":"17","author":"Gros","year":"2024","journal-title":"Therap Adv Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae188\/61028582\/jjae188.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/7\/jjae188\/61028582\/jjae188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/7\/jjae188\/61028582\/jjae188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:21:51Z","timestamp":1752571311000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjae188\/7920833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae188","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2024,12,11]]},"article-number":"jjae188"}}